Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E8.68 EPS (ttm)9.21 Insider Own0.30% Shs Outstand1.31B Perf Week-2.48%
Market Cap104.58B Forward P/E10.78 EPS next Y7.42 Insider Trans-15.72% Shs Float1.30B Perf Month-2.93%
Income12.21B PEG- EPS next Q2.12 Inst Own77.40% Short Float1.76% Perf Quarter11.52%
Sales28.47B P/S3.67 EPS this Y-16.50% Inst Trans0.01% Short Ratio2.45 Perf Half Y21.03%
Book/sh17.35 P/B4.61 EPS next Y-15.34% ROA21.10% Target Price84.35 Perf Year9.90%
Cash/sh16.13 P/C4.96 EPS next 5Y-8.43% ROE61.90% 52W Range63.76 - 86.27 Perf YTD11.65%
Dividend2.08 P/FCF9.69 EPS past 5Y41.20% ROI31.00% 52W High-7.32% Beta1.17
Dividend %2.60% Quick Ratio3.20 Sales past 5Y29.40% Gross Margin84.90% 52W Low25.39% ATR1.59
Employees9000 Current Ratio3.40 Sales Q/Q-8.20% Oper. Margin57.80% RSI (14)44.75 Volatility1.62% 1.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.60% Profit Margin42.90% Rel Volume0.78 Prev Close81.17
ShortableYes LT Debt/Eq1.16 EarningsOct 26 AMC Payout21.30% Avg Volume9.30M Price79.95
Recom2.40 SMA20-3.20% SMA500.58% SMA20011.52% Volume7,214,399 Change-1.50%
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Oct-16-17 12:01PM  [$$] More Biotechs That Can Beat Q3 Views Barrons.com
11:40AM  Berkshire Hathaway And 6 Other Piggyback Stocks To Profit From Forbes
09:31AM  The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon Zacks
08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
08:00AM  Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research Business Wire
07:45AM  Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field Investor's Business Daily
Oct-15-17 11:05PM  [$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene The Wall Street Journal
Oct-13-17 04:37PM  Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences Zacks
11:33AM  Its Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock InvestorPlace
07:02AM  Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy InvestorPlace
06:05AM  3 Healthcare Value Stocks Motley Fool
Oct-12-17 06:45PM  Non-Alcoholic Steatohepatitis 2017 Progress Update Zacks
04:01PM  Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017 Business Wire
02:35PM  Top 5 Biotech Stocks for 2017 Investopedia
06:00AM  Celgene, Biogen Are Poised to Break Out: A Technical View Investopedia
06:00AM  5 Game-Changing Cancer Drug Innovations Being Developed Right Now Motley Fool
Oct-11-17 04:36PM  Is AbbVie the Best Dividend Stock in Healthcare? Motley Fool
Oct-10-17 10:57AM  Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow InvestorPlace
06:02AM  $50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much Motley Fool
Oct-08-17 08:18AM  Bitcoin vs. Biotech: Which Is the Smarter Investment? Motley Fool
Oct-07-17 01:00PM  Here's Why Juno Therapeutics Stock May Still Be Worth Buying Motley Fool
10:29AM  This Dirt-Cheap Biotech Stock Is a Bargain to Buy Motley Fool
Oct-06-17 04:10PM  Here's What's Has Happened in the HCV Space Lately Zacks
11:38AM  Gilead Sciences & AbbVie: Mother Always Told Me to Share Barrons.com
11:09AM  Life (Science) Lessons: The Hows And Whos To Play Biotech Benzinga
07:18AM  Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now? Motley Fool
Oct-05-17 11:50PM  5 Undervalued Stocks With Free Cash Flow to Burn Kiplinger
05:38PM  Needelman Asset Management Inc Buys Gilead Sciences Inc GuruFocus.com
05:00PM  Big biotech trades: 5 plays CNBC Videos
10:12AM  Gilead Sciences, Inc. : GILD-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 5, 2017 Capital Cube
09:35AM  Gilead Sciences: How You'll Know It's Time to Buy Barrons.com
Oct-04-17 02:00PM  Why Biotech's Rally May Push These 8 Stocks Even Higher Investopedia
11:40AM  Cancer-Cure Makers Make Great Takeover Stocks Forbes
11:39AM  Gilead Sciences: Better Safe ThanNot Working At All Barrons.com
08:00AM  The Hepatitis Drug Market Is Worse Than Wall Street Realizes Bloomberg
08:00AM  Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens Business Wire
03:01AM  Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir Business Wire
Oct-03-17 06:14PM  The 5 Best M&A Deals of 2017 (So Far!) Zacks
10:42AM  Why bluebird bio, Inc. Stock Gained 10% in September Motley Fool
09:24AM  Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs? Zacks
08:45AM  Gilead Sciences Completes Acquisition of Kite Pharma, Inc. Business Wire
08:00AM  Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc. Business Wire
06:03AM  Good News and Bad News for Gilead Sciences: Which Carries More Weight? Motley Fool
Oct-02-17 05:00PM  What the traders bought today: 7 trades CNBC Videos
03:56PM  Bluebird Bio: So Much for That Gilead Boost Barrons.com
09:00AM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Motley Fool
08:40AM  Merck Drops Two HCV Combination Programs Amid Competition Zacks
Oct-01-17 07:03PM  Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences? Motley Fool
05:07PM  Merck Hepatitis C exit could lift the spaces two remaining drugmakers MarketWatch
Sep-29-17 09:28AM  How Will Trump's Proposed Tax Reform Impact Drug Companies? Zacks
08:05AM  Merck to stop development of hepatitis C treatments Reuters
Sep-28-17 04:47PM  Why Gilead Sciences, Pier 1 Imports, and PetMed Express Slumped Today Motley Fool
04:31PM  Gilead Tumbles On Report HIV-Drug Whistleblower Case Reopened Investor's Business Daily
03:55PM  Gilead Sciences: 'We Don't Think That His Departure Is a Red Herring' Barrons.com
03:51PM  Gilead shares decline nearly 5% after COO says he will retire MarketWatch
03:50PM  Is It Too Late To Buy Gilead Sciences Inc (GILD)? Simply Wall St.
09:10AM  Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China Zacks
06:02AM  Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis? Motley Fool
Sep-27-17 04:30PM  Kevin Young CBE, Gileads Chief Operating Officer, to Retire Business Wire
01:16PM  [$$] Gilead's China Entrance Looks Crowded Barrons.com
08:20AM  Today's Research Reports on Stocks to Watch: Gilead Sciences and TherapeuticsMD ACCESSWIRE
Sep-26-17 04:29PM  Revival of Gilead Whistleblower's Lawsuit Should Stoke Fear In Big Pharma Forbes
12:51PM  Gilead Sciences: New Market, Same Problem? Barrons.com
10:52AM  ETFs with exposure to Gilead Sciences, Inc. : September 26, 2017 Capital Cube
09:30AM  Kite Pharma Triples So Far in 2017: What's Driving the Rally? Zacks
08:30AM  Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period Business Wire
08:04AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Sep-25-17 03:16PM  [$$] Getting Ready for Gilead's CAR-T Barrons.com
11:02AM  Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy? Barrons.com
07:55AM  China Food and Drug Administration Approves Gileads Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection Business Wire
Sep-22-17 04:00PM  Oddly, Juno Therapeutics Is Jumping 11.3% Today Motley Fool
03:14PM  Gilead's (GILD) Epclusa Receives Label Expansion in Canada Zacks
10:00AM  Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion? Motley Fool
07:43AM  3 Big Biotech Stocks to Buy This Fall Motley Fool
07:03AM  Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy? InvestorPlace
06:00AM  Gilead, Amgen, and Biogen May Lift Biotech Higher Investopedia
Sep-21-17 05:31PM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
03:30PM  Why Gilead Sciences Is Flying High With Kite Forbes
08:04AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
05:59AM  Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV CNW Group
Sep-20-17 06:57PM  These Stocks Pay You to Own Them TheStreet.com
08:04AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Sep-19-17 09:55AM  Should Value Investors Consider Gilead Sciences (GILD) Stock? Zacks
09:46AM  Your first trade for Tuesday, September 19 CNBC
08:07AM  Taking On Exposure to Innovative Biotechnology Stocks Market Realist
07:09AM  Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade InvestorPlace
06:09AM  Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors Motley Fool
Sep-18-17 05:59PM  "Fast Money" final trades: AMD, INTC and more CNBC Videos
03:07PM  Why Bellicum Pharmaceuticals Stock Is Rising Today Motley Fool
12:36PM  Benefitting from IBBs Lower Expense Ratio Market Realist
11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late? Barrons.com
10:50AM  The IBB Biotechnology ETF: The Drugs You Need? Market Realist
10:30AM  3 Value Stocks for Smart Investors Motley Fool
Sep-17-17 12:17PM  3 Great Income Stocks That Could Double Their Dividends Motley Fool
Sep-15-17 02:21PM  AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Investor's Business Daily
11:07AM  After Gilead Sciences, More Biotech M&A? Barrons.com
07:45AM  3 Reasons Why Gilead Sciences Stock Is a Buy Now Motley Fool
06:00AM  3 Dividend Healthcare Stocks Motley Fool
Sep-14-17 06:45PM  Gilead Prices $3 Billion of Senior Unsecured Notes Business Wire
06:18PM  ETFs with exposure to Gilead Sciences, Inc. : September 14, 2017 Capital Cube
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM